Bavarian Nordic releases more specific guidance - downgrades expectations

Although Covid-19 has not disrupted sales of Bavarian Nordic's ebola vaccine, its hands are still tied in other business areas, leading the firm to downgrade its financial guidance.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic's potential Covid-19 vaccine has been hogging the spotlight over the past few months, but the company has also been working on its other business areas - where Covid-19 is more of a hindrance than a help.

This has led Bavarian Nordic to release more specific financial guidance at the lower end of its original expectations.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs